VP-16-213 chemotherapy for advanced squamous cell carcinoma and adenocarcinoma of the lung.

No abstract is available for this paper.

• Publication year

  1978

• Venue

  Cancer treatment reports

• Publication date

  1978-05-01

• Fields of study

  Medicine

• Identifiers
  PMID 657168
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dose response evaluation of adriamycin in human neoplasia

  1977cited by this paper
• Therapy of advanced squamous carcinoma of the lung. Cyclophosphamide versus “COMB”

  1977cited by this paper
• Platinum-based polychemotherapy versus dianhydrogalactitol in advanced non-small cell lung cancer.

  1977cited by this paper
• VP-16-213 versus polychemotherapy in patients with advanced small cell lung cancer.

  1976cited by this paper
• Cyclophosphamide and CCNU in the treatment of inoperable small cell carcinoma and adenocarcinoma of the lung.

  1976cited by this paper
• A clinical trial of the oral form of 4'-demethyl-epipodophyllotoxin-beta-D ethylidene glucoside (NSC 141540) VP 16-213.

  1975cited by this paper
• Activity of a new glycosidic lignan derivative (VP 16-213) related to podophyllotoxin in experimental tumors.

  1973cited by this paper

• Phase II study of carboplatin in untreated, inoperable non-small-cell lung cancer

  2008cites this paper
• Experience with ifosfamide combinations (etoposide or DDP) in non-small cell lung cancer

  2004cites this paper
• Podophyllotoxin derivative VP 16-213

  2004cites this paper
• Phase II study of mitomycin C, etoposide and vindesine in metastatic stage IV non-small-cell lung cancer

  2004cites this paper
• VP16-213 and cyclophosphamide in non oat cell bronchogenic carcinoma

  2004cites this paper
• The podophyllotoxin derivatives VP16-213 and VM26

  2004cites this paper
• Carboplatin and etoposide in advanced lung cancer: — a phase I study

  2004cites this paper
• cis-platinum and etoposide combination chemotherapy of advanced non-oat cell bronchogenic carcinoma

  2004cites this paper
• Phase II trial of VP16-213 in non-small cell lung cancer (NSCLC)

  2004cites this paper
• Etoposide in patients with previously untreated non-small-cell lung cancer: a phase I study

  2004cites this paper
• VP16-213 (Etoposide)

  2004cites this paper
• A phase II study of weekly high-dose cisplatin combined with oral etoposide in advanced non-small-cell lung cancer

  1997cites this paper
• Chemotherapy for advanced non-small cell lung cancer: past, present, and future.

  1997cites this paper
• Phase I clinical and pharmacokinetic study of a 14-day infusion of etoposide in patients with lung cancer.

  1993cites this paper
• Carboplatin plus oral etoposide in the management of unresectable non-small cell lung cancer. Preliminary results of a Vanderbilt trial.

  1992cites this paper
• Carboplatin plus oral etoposide in the management of advanced, non-small cell lung cancer: preliminary results of a Vanderbilt trial.

  1992cites this paper
• A Study of Oral Etoposide, Infusional Cisplatin, and Infusional 5‐Fluorouracil for Locally Advanced or Metastatic Non‐Small-Cell Lung Cancer: A Mid‐Atlantic Oncology Program Study

  1992cites this paper
• Symptomatic treatment versus combination chemotherapy for patients with extensive non‐small cell lung cancer

  1991cites this paper
• Etoposide and Mitomycin in the Treatment of Non‐Small‐Cell Lung Cancer: A Phase I‐II Evaluation

  1991cites this paper
• [Combination radiotherapy and chemotherapy in bronchial cancer: benefits and limitations].

  1990cites this paper
• Phase II studies with carboplatin in non-small cell lung cancer.

  1990cites this paper
• A novel pharmacodynamically based approach to dose optimization of carboplatin when used in combination with etoposide.

  1989cites this paper
• A comparison of cis-platinum-vindesine and cis-platinum-etoposide combined with radiotherapy for previously untreated localized inoperable non-small cell lung cancer.

  1989cites this paper
• Single-agent chemotherapy for advanced adenocarcinoma of the lung

  1988cites this paper
• Combination chemotherapy for advanced adenocarcinoma of the lung

  1988cites this paper
• Multimodality treatment of non‐small cell lung cancer: Response to cisplatin, VP‐16, and 5‐FU chemotherapy and to surgery and radiation therapy

  1988cites this paper
• Etoposide and Split‐Dose Cisplatin in Small‐Cell Lung Cancer

  1988cites this paper
• Reply

  1986cites this paper
• ARE WE MAKING PROGRESS IN THE DRUG TREATMENT OF LUNG CANCER?

  1986cites this paper
• Chemotherapy in non-small cell bronchial carcinoma.

  1985cites this paper
• New frontiers in the treatment of lung cancer.

  1985cites this paper
• Unresectable non-small cell lung cancer chemotherapy with high-dose cisplatin and etoposide.

  1985cites this paper
• Update in cancer chemotherapy, Part III: Lung cancer, Part 1.

  1985cites this paper
• VP-16 and cisplatin in the treatment of non-small-cell lung cancer.

  1985cites this paper
• Treatment of non-small cell bronchogenic carcinoma with vinblastine and mitomycin: a Southwest Oncology Group Study.

  1985cites this paper
• Ovarian dysfunction in patients with gestational trophoblastic neoplasia treated with short intensive courses of etoposide (VP‐16‐213)

  1985cites this paper
• Phase II study of etoposide (VP‐16) in the treatment of advanced head and neck cancer

  1985cites this paper
• Etoposid in der Behandlung des inoperablen Bronchuskarzinoms

  1984cites this paper
• Low-Dose Cisplatin and Etoposide in Advanced Non-Small Cell Lung Carcinoma

  1984cites this paper
• [Cisplatin, vindesine and VP 16-213 in the treatment of inoperable non-small cell bronchial carcinoma. A clinical phase II study].

  1984cites this paper
• Mitomycin‐C, etoposide, cisplatin, and hexamethylmelamine (MEPH) as a second‐line regimen in lung cancer

  1984cites this paper
• cis-Platinum (DDP) and VP 16-213 (etoposide) combination chemotherapy for advanced non-small cell lung cancer. A phase II clinical trial.

  1984cites this paper
• Small-cell carcinoma of the lung 24 years after post-operative irradiation for breast carcinoma.

  1984cites this paper
• Etoposide: A Semisynthetic Epipodophyllotoxin Chemistry, Pharmacology, Pharmacokinetics, Adverse Effects and Use as an Antineoplastic Agent

  1984cites this paper
• Etoposide infusions for treatment of metastatic lung cancer.

  1984cites this paper
• New agents in non-small cell lung cancer.

  1984cites this paper
• Etoposid in der Behandlung des Bronchuskarzinoms

  1984cites this paper
• Etoposide (VP-16) in the treatment of lung cancer.

  1983cites this paper
• [Results of drug therapy of inoperable non-small cell lung carcinoma with VP 16-213 (Etoposide) and cis-platin. A phase II study].

  1983cites this paper
• Chemotherapy of non-small cell lung cancer: a reappraisal and a look to the future.

  1983cites this paper
• Randomized study of cyclophosphamide, doxorubicin, and etoposide (VP16-213) with or without cisplatinum in non-small cell lung cancer.

  1983cites this paper
• Chemotherapy of metastatic non-small cell bronchogenic carcinoma.

  1983cites this paper
• Randomized phase II comparison of methotrexate with or without L-asparaginase in non-small cell cancer of the lung.

  1982cites this paper
• Review of etoposide single-agent activity.

  1982cites this paper
• A Critical Review of its Activity

  1982cites this paper
• Chemotherapy and radiation therapy for non-small cell lung carcinoma.

  1982cites this paper
• VP-16-213 (etoposide): the mandrake root from Issyk-Kul.

  1982cites this paper
• Combination chemotherapy with cisplatin and etoposide in bronchogenic squamous cell carcinoma and adenocarcinoma. A study by the EORTC lung cancer working party (Belgium)

  1982cites this paper
• Etoposide as single agent and in combination chemotherapy of bronchogenic carcinoma.

  1982cites this paper
• A review of etoposide in patients with non-small-cell lung cancer (NSCLC).

  1982cites this paper
• Phase II trial of VP-16-213 in non-small-cell lung cancer.

  1982cites this paper
• Etoposide alone and in combination with cyclophosphamide, adriamycin and cis-platinum in patients with Mo and Mi non-small-cell lung cancer.

  1982cites this paper
• Phase II trial of etoposide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.

  1982cites this paper
• Etoposide and cis-platinum in non-small-cell bronchogenic carcinoma.

  1982cites this paper
• Evaluation of VP-16-213, cyclophosphamide, doxorubicin, and cisplatin (V-CAP) in advanced large cell lung cancer.

  1981cites this paper
• Preliminary study of the combination, dianhydrogalactitol, cis-diaminedichloroplatinum (II), and VP-16-213 in patients with advanced cancer.

  1981cites this paper
• [Etoposide. A new highly effective cytostatic agent in anaplastic small-cell bronchial carcinoma, other solid tumors and hemoblastoses].

  1981cites this paper
• Etoposide: a new anti-cancer agent.

  1981cites this paper
• [Randomized phase II study with VP-16-213 (etoposide) in the treatment of advanced breast cancer].

  1981cites this paper
• Etoposid (VP 16-213)

  1981cites this paper
• [Etoposide VP 16--213)--a podophyllotoxinderivative with high antitumor activity (author's transl)].

  1981cites this paper
• Cyclophosphamide and VP-16-213 with or without cisplatin in squamous cell and small cell lung cancers.

  1981cites this paper
• MULTISITE INTRADERMAL ANTIRABIES VACCINATION

  1981cites this paper
• [Results of chemotherapy of inoperable, non-small-cell bronchial carcinomas].

  1980cites this paper
• Phase II evaluation of the combination of triazinate, cyclophosphamide, doxorubicin, and cis-diamminedichloroplatinum(II) in patients with advanced adenocarcinoma of the lung.

  1980cites this paper
• The epipodophyllotoxin derivatives VM-26 and VP-16-213, 1976-1979, a review.

  1980cites this paper
• Cancer Chemo- and Immunopharmacology

  1980cites this paper
• Phase II trial of VP-16-213 in the treatment of advanced squamous cell carcinoma of the cervix and adenocarcinoma of the ovary: a Gynecologic Oncology Group Study.

  1979cites this paper
• Etoposide (VP-16-213).

  1979cites this paper
• Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies.

  1979cites this paper
• Evaluation of response criteria in advanced lung cancer

  1979cites this paper
• VP-16, Cyclophosphamide, Adriamycin and Cis-platinum (V:CAP-I) in Patients with Metastatic Adenocarcinoma of the Lung 1

  1979cites this paper